ClinicalTrials.gg
CompletedNCT01212744Updated Feb 26, 2019Results posted

Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)

A Phase 2 interventional study of rAvPAL-PEG in Phenylketonuria, sponsored by BioMarin Pharmaceutical. Completed at 9 sites in United States. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-02-26.

Sponsored by BioMarin Pharmaceutical · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
16 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing pegvaliase in Phenylketonurias — 1 open to participants now, 2 under way, 1 of them phase 3. pegvaliase · Phenylketonurias.

Enrollment
9th of 10
16 · median 39
Started
2011
the only one that year
Phase 2
4 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
10 of 10
BioMarin Pharmaceutical

Among the 10 studies testing pegvaliase in Phenylketonurias, this one is the 9th largest by enrollment, is the only one that started in 2011, is one of 4 in phase 2, and was the 4th registered.

Phenylketonurias

191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.

Browse Phenylketonurias studies →

Open to participants now

1 of the 10 studies testing pegvaliase in Phenylketonurias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About pegvaliase

pegvaliase: first FDA approval 2018 (PALYNZIQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 16 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing pegvaliase in Phenylketonurias, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of daily administration of rAvPAL-PEG on the reduction of blood Phe concentrations in subjects with PKU.

Read the detailed description

This 16-week multi-center, open-label, Phase 2 study is designed to evaluate the safety, tolerability,and efficacy of daily SC injections of rAvPAL-PEG in subjects with PKU. Subjects who are naïve to prior treatment with rAvPAL-PEG and who have met the other study eligibility criteria will be enrolled at approximately 8 sites in the US and Canada. Up to 6 daily dose levels of rAvPAL-PEG are planned and may be assessed during this study (0.06 mg/kg/day, 0.1 mg/kg/day, 0.2 mg/kg/day;0.4 mg/kg/day, 0.6 mg/kg/day, or 0.8 mg/kg/day). Enrollment will begin with the 0.4 mg/kg/day dose level and additional higher or lower doses may be added. The additional dose levels chosen for assessment will be based on the safety (systemic reaction or clinically significant abnormal laboratory test results assessed as related to study drug) and efficacy (blood Phe reduction to less than or equal to 60 μmol/L) information of at least 3 subjects with at least 2 weeks of daily dosing with rAvPAL-PEG. Initiation of dosing at higher or lower dose levels will be per the determination of the Sponsor's Medical Officer in consultation with the Investigator.

03

Conditions studied

  • Phenylketonuria

Browse trials for

Keywords

  • PEG PAL; PKU; injection;
04

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of PKU with both of the following: current blood Phe concentration of ≥ 600 micromol/L at screening and average blood Phe concentration of ≥ 600 micromol/L over the past 3 years, using available data
  • Evidence that the subject is a non-responder to Kuvan® treatment (ie, 4 weeks of treatment with 20 mg/kg/day of Kuvan, insufficient response per investigator determination, and treatment end date ≥ 14 days prior to Day 1 [ie, first dose]). Subjects who have had a previous response to Kuvan® treatment but are not currently taking Kuvan® because of noncompliance and have been off treatment for ≥ 4 months prior to screening are eligible for participation.
  • Willing and able to provide written, signed , or, in the case of participants under the age of 18, provide written assent (if required) and written informed consent by a legally authorized representative, after the nature of the study has been explained, and prior to any research-related procedures.
  • Willing and able to comply with all study procedures.
  • Between the ages of 16 and 70 years, inclusive.
  • Negative pregnancy test at screening and willing to have additional pregnancy tests performed during the study for females of only. Females considered not of childbearing potential are those who have been in menopause for at least 2 years or have had a tubal ligation at least 1 year prior to screening, or who have had a total hysterectomy.
  • Willing to use an acceptable method of while participating in the study (sexually active subjects only).
  • Maintained a stable diet with no significant modifications during the 4 weeks preceding the administration of study drug.
  • In generally good health as evidenced by physical examination, clinical laboratory evaluations (hematology, chemistry, and urinalysis), and at screening.

Exclusion criteria

Exclusion Criteria:

  • Prior use of rAvPAL-PEG.
  • Use of any product or investigational medical device within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
  • Use of any medication that is intended to treat PKU within 14 days prior to the administration of study drug.
  • Use or planned use of any injectable drugs containing PEG (other than rAvPAL-PEG), including Depo-Provera, within 3 months prior to screening and during study participation.
  • Known to rAvPAL-PEG .
  • Breastfeeding at screening or planning to become pregnant (self or partner) or to breastfeed at any time during the study.
  • Concurrent disease or condition that would interfere with study participation or safety (eg, history or presence of cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, oncologic, or psychiatric disease).
  • Any condition that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study.
  • (ALT) concentration > 2 times the .
  • Creatinine > 1.5 times the upper limit of normal.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    rAvPAL-PEG

    rAvPAL-PEG in varying doses

    Drug: rAvPAL-PEG

Interventions

  • 0.06 mg/kg/day, 0.1 mg/kg/day, 0.2 mg/kg/day, 0.4 mg/kg/day, 0.6 mg/kg/day, 0.8 mg/kg/day

    Also known as: Recombinant Anabaena variabilis phenylalanine ammonia lyase

06

What researchers measure

Primary outcomes

  1. Blood Phenylalanine Concentration

    Plasma Phe

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Study Drug Related Adverse Events

    Safety will be evaluated on the incidence of AEs and clinically significant changes in vital signs as well as clinical labs and ECG. Please refer to AE section below for comprehensive listing of all adverse events recorded during study.

    Time frame: Weekly

  2. Percentage of Participants With PAL IgG Antibody Percentage of Participants With Positive PAL IgG

    Antibody against phenylalanine ammonia lyase (PAL)

    Time frame: Baseline, Week 16

  3. Plasma Concentrations of rAvPAL-PEG (BMN 165)

    Measurements taken pre-dose

    Time frame: Baseline, Week 8, Week 13

  4. Percentage of Participants With PEG-IgG Antibody Positivity

    Antibodies against polyethylene glycol (PEG) of the IgG isotype

    Time frame: Baseline, Week 16

  5. Percentage of Participants With PAL-IgM Antibody Positivity

    Antibodies against phenylalanine ammonia lyase (PAL) of the IgM isotype

    Time frame: Baseline, Week 16

  6. Percentage of Participants With PEG-IgM Antibody Positivity

    Antibodies against polyethylene glycol (PEG) of the IgM isotype

    Time frame: Baseline, Week 16

  7. Percentage of Participants With Neutralizing Antibody Positivity

    Antibody positivity over time

    Time frame: Baseline, Week 16

  8. Percentage of Participants With PAL-IgE Antibody Positivity

    Antibodies against phenylalanine ammonia lyase (PAL) of the IgE isotype

    Time frame: Baseline, Week 16

  9. Percentage of Participants With PAL-PEG-IgE Antibody Positivity

    Antibodies against phenylalanine ammonia lyase (PAL)-polyethylene glycol (PEG) of the IgE isotype

    Time frame: Baseline, Week 16

07

Results

Posted Feb 26, 2019

Participant flow

Participant flow — Overall Study
MilestonerAvPAL-PEG
Started16
Completed15
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryBlood Phenylalanine Concentration

Plasma Phe

Time frame:
Baseline, Week 16
Reported as:
Mean · umol/L
Blood Phenylalanine Concentration
umol/LrAvPAL-PEG
Baseline1482.1 ± 363.46
Week 161566.0 ± 586.11
SecondaryStudy Drug Related Adverse Events

Safety will be evaluated on the incidence of AEs and clinically significant changes in vital signs as well as clinical labs and ECG. Please refer to AE section below for comprehensive listing of all adverse events recorded during study.

Time frame:
Weekly
Reported as:
Count of participants · Participants
Study Drug Related Adverse Events
ParticipantsTotal
Study Drug Related Adverse Events16
SecondaryPercentage of Participants With PAL IgG Antibody Percentage of Participants With Positive PAL IgG

Antibody against phenylalanine ammonia lyase (PAL)

Time frame:
Baseline, Week 16
Reported as:
Number · Percentage
Percentage of Participants With PAL IgG Antibody Percentage of Participants With Positive PAL IgG
PercentageTotal
Baseline12.5
Week 16100.0
SecondaryPlasma Concentrations of rAvPAL-PEG (BMN 165)

Measurements taken pre-dose

Time frame:
Baseline, Week 8, Week 13
Reported as:
Mean · ng/mL
Plasma Concentrations of rAvPAL-PEG (BMN 165)
ng/mLrAvPAL-PEG
Baseline-Day 1, 1 Hour Predose0.000 ± 0.0000
Week 8-Day 52, 1 Hour Predose2425.608 ± 8532.2431
Week 13-Day 89, Predose1116.364 ± 2013.9676
SecondaryPercentage of Participants With PEG-IgG Antibody Positivity

Antibodies against polyethylene glycol (PEG) of the IgG isotype

Time frame:
Baseline, Week 16
Reported as:
Number · Percentage
Percentage of Participants With PEG-IgG Antibody Positivity
PercentageTotal
Baseline25.0
Week 1675.0
SecondaryPercentage of Participants With PAL-IgM Antibody Positivity

Antibodies against phenylalanine ammonia lyase (PAL) of the IgM isotype

Time frame:
Baseline, Week 16
Reported as:
Number · Percentage
Percentage of Participants With PAL-IgM Antibody Positivity
PercentageTotal
Baseline12.5
Week 1675.0
SecondaryPercentage of Participants With PEG-IgM Antibody Positivity

Antibodies against polyethylene glycol (PEG) of the IgM isotype

Time frame:
Baseline, Week 16
Reported as:
Number · Percentage
Percentage of Participants With PEG-IgM Antibody Positivity
PercentageTotal
Baseline31.3
Week 1650.0
SecondaryPercentage of Participants With Neutralizing Antibody Positivity

Antibody positivity over time

Time frame:
Baseline, Week 16
Reported as:
Number · Percentage
Percentage of Participants With Neutralizing Antibody Positivity
PercentageTotal
Baseline0.0
Week 160.0
SecondaryPercentage of Participants With PAL-IgE Antibody Positivity

Antibodies against phenylalanine ammonia lyase (PAL) of the IgE isotype

Time frame:
Baseline, Week 16
Reported as:
Number · Percentage
Percentage of Participants With PAL-IgE Antibody Positivity
PercentageTotal
Baseline0.0
Week 160.0
SecondaryPercentage of Participants With PAL-PEG-IgE Antibody Positivity

Antibodies against phenylalanine ammonia lyase (PAL)-polyethylene glycol (PEG) of the IgE isotype

Time frame:
Baseline, Week 16
Reported as:
Number · Percentage
Percentage of Participants With PAL-PEG-IgE Antibody Positivity
PercentageTotal
Baseline0.0
Week 160.0

Adverse events

Collected over Week 0- Week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rAvPAL-PEG0/16 (0%)1/16 (6.3%)16/16 (100%)
Most frequent serious events
Most frequent serious events
EventrAvPAL-PEG
AngioedemaSkin and subcutaneous tissue disorders1/16
Most frequent other events
Showing 10 of 120
Most frequent other events
EventrAvPAL-PEG
ArthralgiaMusculoskeletal and connective tissue disorders12/16
HeadacheNervous system disorders10/16
DizzinessNervous system disorders9/16
Injection site erythemaGeneral disorders8/16
Injection site reactionGeneral disorders8/16
Injection site painGeneral disorders7/16
Injection site bruisingGeneral disorders6/16
Rash generalisedSkin and subcutaneous tissue disorders6/16
DiarrhoeaGastrointestinal disorders5/16
PyrexiaGeneral disorders5/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)rAvPAL-PEG
Mean32.2 ± 8.27
Age, Customized
Age, Customized(Participants)rAvPAL-PEG
< 18 years of age0
> or = 18 years of age16
Sex: Female, Male
Sex: Female, Male(Participants)rAvPAL-PEG
Female13
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)rAvPAL-PEG
Hispanic or Latino0
Not Hispanic or Latino16
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)rAvPAL-PEG
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White16
Other0
08

Study locations

9 sites
  • The Children's Hospital
    Aurora, Colorado 80045, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Weisskopf Child Evaluation Center / University of Louisville
    Louisville, Kentucky 40202, United States
  • University of Missouri
    Columbia, Missouri 65212, United States
  • Washington University Center for Applied Research Sciences
    Saint Louis, Missouri 63110, United States
  • Albany Medical Center
    Albany, New York 12208, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • University of Wisconsin-Madison
    Madison, Wisconsin 53705, United States
09

References and documents

Publications

  • Burton BK, Longo N, Vockley J, Grange DK, Harding CO, Decker C, Li M, Lau K, Rosen O, Larimore K, Thomas J; PAL-002 and PAL-004 Investigators. Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up. Mol Genet Metab. 2020 Aug;130(4):239-246. doi: 10.1016/j.ymgme.2020.06.006. Epub 2020 Jun 16. PubMed 32593547 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2019, 3 years 10 months after primary completion. A results delay was requested in Aug 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2010
First posted
Oct 1, 2010
Start
Mar 2011
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Results delay requested
Aug 17, 2017
Results first posted
Feb 26, 2019
Last update
Feb 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01212744
Responsible party
Sponsor
First posted
Oct 1, 2010
Start date
Mar 2011
Primary completion
Apr 2015
Completion
Apr 2015
Results posted
Feb 26, 2019
Last update
Feb 26, 2019

Study contacts

Ari Gershman, MD
study director · BioMarin Pharmaceutical

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegvaliase

Start the discussion